0001127602-16-044742.txt : 20160303
0001127602-16-044742.hdr.sgml : 20160303
20160303145413
ACCESSION NUMBER: 0001127602-16-044742
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160301
FILED AS OF DATE: 20160303
DATE AS OF CHANGE: 20160303
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: GILEAD SCIENCES INC
CENTRAL INDEX KEY: 0000882095
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 943047598
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 333 LAKESIDE DR
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
BUSINESS PHONE: 6505743000
MAIL ADDRESS:
STREET 1: 333 LAKESIDE DR
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MILLIGAN JOHN F
CENTRAL INDEX KEY: 0001191589
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19731
FILM NUMBER: 161480680
MAIL ADDRESS:
STREET 1: C/O GILEAD SCIENCES, INC.
STREET 2: 333 LAKESIDE DRIVE
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2016-03-01
0000882095
GILEAD SCIENCES INC
GILD
0001191589
MILLIGAN JOHN F
GILEAD SCIENCES, INC.
333 LAKESIDE DRIVE
FOSTER CITY
CA
94404
1
1
President, COO and Director
Common Stock
2016-03-01
4
M
0
112000
16.395
A
1170963
D
Common Stock
2016-03-01
4
S
0
112000
87.7946
D
1058963
D
Non-qualified Stock Option (Right to Buy)
16.395
2016-03-01
4
M
0
112000
0
D
2017-01-22
Common Stock
112000
448000
D
The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
Sale prices reported for the transactions reported here range from $87.31 to $88.14. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
/s/ Brett A. Pletcher by Power of Attorney for John F. Milligan
2016-03-03